相关实验视频
Updated: Jun 4, 2025

07:44
A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
294
对急性肺栓塞治疗的理性方法
Michela Faggioni1, Jay Giri2,3, Lauren Glassmoyer3
1Division of Cardiovascular Medicine, Department of Medicine, University of California, San Francisco, California, USA.
Annual review of medicine
|January 2, 2025
概括
由于新的选择但指导方针有限,急性肺栓塞 (PE) 治疗是复杂的. 本综述提供了对PE风险分层和治疗选择的实用方法,以改善患者护理.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 紧急医疗 紧急医疗
背景情况:
- 急性肺栓塞 (PE) 是全球疾病和死亡的重要原因之一.
- 尽管治疗方法取得了进展,但对PE的临床决策仍然具有挑战性.
- 缺乏可靠的临床试验数据和明确的指导方针使患者管理复杂化.
研究的目的:
- 提出一种实用和当前的方法来管理急性肺栓塞患者.
- 专注于PE患者的风险分层策略.
- 在不断发展的PE疗法背景下指导治疗选择.
主要方法:
- 关于肺栓塞的当前文献和临床指导方针的审查.
- 讨论PE的风险分层工具和得分.
- 对PE的新兴和已确定的治疗选择进行分析.
主要成果:
- 在过去的十年中,PE的新治疗方式出现了.
- 风险分层对于定制PE治疗至关重要.
- 选择治疗需要仔细考虑个体患者的因素和现有证据.
结论:
- 一种结构化的PE管理方法,强调风险分层是必不可少的.
- 临床医生需要实际指导,以导航复杂的治疗决策在PE.
- 需要进一步的研究和指导方针的制定,以优化急性肺栓塞的护理.
相关概念视频
Acute Respiratory Failure-V
123
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
123
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
133
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
133
Flail Chest-II
160
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
160
Anticoagulant Drugs: Low-Molecular-Weight Heparins
607
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
607
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
135
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
135

